MediWound Ltd. announced the appointments of Mr. Samuel Moed and Mr. David Fox to its Board of Directors to serve until the 2020 annual meeting of shareholders. Stephen T. Wills, MediWound’s Chairman since 2018, was named Executive Chairman. Mr. Samuel Moed joins the MediWound board having recently retired as an executive from Bristol-Myers Squibb. In his most recent capacity as Senior Vice President, Corporate Strategy, Mr. Moed led the strategic planning of the company in all major business activities worldwide. His most recent focus has been on the $90 billion acquisition and integration of Celgene by BMS. Previously, Mr. Moed oversaw strategy for BMS’s Worldwide Pharmaceuticals Group, encompassing a range of global strategic initiatives, and managed a global portfolio of strategic alliances. Mr. David Fox brings to the MediWound Board decades of leadership and deal experience and insight. Mr. Foxwas most recently a partner at Kirkland & Ellis LLP and served as a member of its Global Executive Management Committee until 2019.